Literature DB >> 29285493

Alectinib in untreated anaplastic lymphoma kinase-positive non-small cell lung cancer.

Anne-Marie Ruppert1,2, Xavier Mignard1, Marie Wislez1,2.   

Abstract

Entities:  

Year:  2017        PMID： 29285493      PMCID： PMC5733330          DOI： 10.21037/atm.2017.09.05

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  10 in total

1.  Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study.

Authors:  Anne McLeer-Florin; Denis Moro-Sibilot; Adrien Melis; Dimitri Salameire; Christine Lefebvre; Françoise Ceccaldi; Florence de Fraipont; Elisabeth Brambilla; Sylvie Lantuejoul
Journal:  J Thorac Oncol       Date:  2012-02       Impact factor: 15.609

2.  Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.

Authors:  Toyoaki Hida; Hiroshi Nokihara; Masashi Kondo; Young Hak Kim; Koichi Azuma; Takashi Seto; Yuichi Takiguchi; Makoto Nishio; Hiroshige Yoshioka; Fumio Imamura; Katsuyuki Hotta; Satoshi Watanabe; Koichi Goto; Miyako Satouchi; Toshiyuki Kozuki; Takehito Shukuya; Kazuhiko Nakagawa; Tetsuya Mitsudomi; Nobuyuki Yamamoto; Takashi Asakawa; Ryoichi Asabe; Tomohiro Tanaka; Tomohide Tamura
Journal:  Lancet       Date:  2017-05-10       Impact factor: 79.321

3.  Ceritinib in ALK-rearranged non-small-cell lung cancer.

Authors:  Alice T Shaw; Dong-Wan Kim; Ranee Mehra; Daniel S W Tan; Enriqueta Felip; Laura Q M Chow; D Ross Camidge; Johan Vansteenkiste; Sunil Sharma; Tommaso De Pas; Gregory J Riely; Benjamin J Solomon; Juergen Wolf; Michael Thomas; Martin Schuler; Geoffrey Liu; Armando Santoro; Yvonne Y Lau; Meredith Goldwasser; Anthony L Boral; Jeffrey A Engelman
Journal:  N Engl J Med       Date:  2014-03-27       Impact factor: 91.245

4.  Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

Authors:  Solange Peters; D Ross Camidge; Alice T Shaw; Shirish Gadgeel; Jin S Ahn; Dong-Wan Kim; Sai-Hong I Ou; Maurice Pérol; Rafal Dziadziuszko; Rafael Rosell; Ali Zeaiter; Emmanuel Mitry; Sophie Golding; Bogdana Balas; Johannes Noe; Peter N Morcos; Tony Mok
Journal:  N Engl J Med       Date:  2017-06-06       Impact factor: 91.245

5.  Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.

Authors:  Alice T Shaw; Tae Min Kim; Lucio Crinò; Cesare Gridelli; Katsuyuki Kiura; Geoffrey Liu; Silvia Novello; Alessandra Bearz; Oliver Gautschi; Tony Mok; Makoto Nishio; Giorgio Scagliotti; David R Spigel; Stéphanie Deudon; Cheng Zheng; Serafino Pantano; Patrick Urban; Cristian Massacesi; Kalyanee Viraswami-Appanna; Enriqueta Felip
Journal:  Lancet Oncol       Date:  2017-06-09       Impact factor: 41.316

6.  First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.

Authors:  Jean-Charles Soria; Daniel S W Tan; Rita Chiari; Yi-Long Wu; Luis Paz-Ares; Juergen Wolf; Sarayut L Geater; Sergey Orlov; Diego Cortinovis; Chong-Jen Yu; Maximillian Hochmair; Alexis B Cortot; Chun-Ming Tsai; Denis Moro-Sibilot; Rosario G Campelo; Tracey McCulloch; Paramita Sen; Margaret Dugan; Serafino Pantano; Fabrice Branle; Cristian Massacesi; Gilberto de Castro
Journal:  Lancet       Date:  2017-01-24       Impact factor: 79.321

7.  ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer.

Authors:  Benjamin Solomon; Marileila Varella-Garcia; D Ross Camidge
Journal:  J Thorac Oncol       Date:  2009-12       Impact factor: 15.609

8.  Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.

Authors:  Sai-Hong Ignatius Ou; Jin Seok Ahn; Luigi De Petris; Ramaswamy Govindan; James Chih-Hsin Yang; Brett Hughes; Hervé Lena; Denis Moro-Sibilot; Alessandra Bearz; Santiago Viteri Ramirez; Tarek Mekhail; Alexander Spira; Walter Bordogna; Bogdana Balas; Peter N Morcos; Annabelle Monnet; Ali Zeaiter; Dong-Wan Kim
Journal:  J Clin Oncol       Date:  2015-11-23       Impact factor: 44.544

9.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Authors:  Alice T Shaw; Dong-Wan Kim; Kazuhiko Nakagawa; Takashi Seto; Lucio Crinó; Myung-Ju Ahn; Tommaso De Pas; Benjamin Besse; Benjamin J Solomon; Fiona Blackhall; Yi-Long Wu; Michael Thomas; Kenneth J O'Byrne; Denis Moro-Sibilot; D Ross Camidge; Tony Mok; Vera Hirsh; Gregory J Riely; Shrividya Iyer; Vanessa Tassell; Anna Polli; Keith D Wilner; Pasi A Jänne
Journal:  N Engl J Med       Date:  2013-06-01       Impact factor: 91.245

10.  Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.

Authors:  Alice T Shaw; Leena Gandhi; Shirish Gadgeel; Gregory J Riely; Jeremy Cetnar; Howard West; D Ross Camidge; Mark A Socinski; Alberto Chiappori; Tarek Mekhail; Bo H Chao; Hossein Borghaei; Kathryn A Gold; Ali Zeaiter; Walter Bordogna; Bogdana Balas; Oscar Puig; Volkmar Henschel; Sai-Hong Ignatius Ou
Journal:  Lancet Oncol       Date:  2015-12-19       Impact factor: 41.316
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.